The UK-based company's differentiated small molecule drug discovery platform was built to deliver a new class of transformative regenerative and neuroprotective therapeutics.

In Jnauray 2023, Pheno announced a licensing deal with Belgium’s largest drugmaker UCB. The exclusive worldwide license agreement will give the UCB access to a pre-clinical-stage program of novel small molecules in return for an undisclosed upfront payment. Pheno will gain the rights to develop, manufacture and commercialize the assets.